Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Non-Current Debt (2023 - 2025)

Historic Non-Current Debt for Perspective Therapeutics (CATX) over the last 3 years, with Q3 2025 value amounting to $1.6 million.

  • Perspective Therapeutics' Non-Current Debt fell 335.78% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 335.78%. This contributed to the annual value of $1.6 million for FY2024, which is 304.3% down from last year.
  • Latest data reveals that Perspective Therapeutics reported Non-Current Debt of $1.6 million as of Q3 2025, which was down 335.78% from $1.6 million recorded in Q2 2025.
  • Perspective Therapeutics' Non-Current Debt's 5-year high stood at $1.7 million during Q1 2023, with a 5-year trough of $1.6 million in Q3 2025.
  • Over the past 3 years, Perspective Therapeutics' median Non-Current Debt value was $1.7 million (recorded in 2024), while the average stood at $1.6 million.
  • Per our database at Business Quant, Perspective Therapeutics' Non-Current Debt crashed by 291.89% in 2024 and then tumbled by 335.78% in 2025.
  • Perspective Therapeutics' Non-Current Debt (Quarter) stood at $1.7 million in 2023, then fell by 3.04% to $1.6 million in 2024, then dropped by 2.58% to $1.6 million in 2025.
  • Its Non-Current Debt stands at $1.6 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.6 million for Q1 2025.